Lv4
450 积分 2022-11-11 加入
Iptacopan: First Approval
10天前
已完结
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
16天前
已完结
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
21天前
已完结
Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy
1个月前
已完结
Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy
2个月前
已完结
Investigating the Effect of Chemical Modifications on the Ribose Sugar Conformation, Watson–Crick Base Pairing, and Intrastrand Stacking Interactions: A Theoretical Approach
3个月前
已完结
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results
3个月前
已完结
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
3个月前
已完结
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
3个月前
已完结
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
3个月前
已完结
皖公网安备34019202002308
